

C31  
CONT. assay the ability of IL-1 traps to block the IL-1-dependent production of IL-6. IL1 Trap 1SC569 (Figs. 26A-26E [SEQ ID NOS: 27 and 28] ) was tested against IL-1-RI.Fc which is the extracellular domain of the IL-1 Type I receptor fused to an Fc domain.

✓  
Please replace the paragraph starting on page 62, line 19, with the following:

C32 Figure 30 shows that the trap 569 (Figs. 26A-26E [SEQ ID NOS: 27 and 28]) is able to antagonize the effects of IL-1 and block the IL-6 production from MRC 5 cells upon treatment with IL-1. At a concentration of 10nM, the trap 569 is able to block the production of IL-6 up to an IL-1 concentration of 3nM. In contrast, the IL-1RI.Fc is a much poorer antagonist of IL-1. It is only able to block the effects of IL-1 up to about 10-20 pM. Thus, the trap 569 is approximately 100x better at blocking IL-1 than IL1RI.Fc.

✓  
Please replace the paragraph starting on page 64, line 4, with the following:

b. IL-13R $\alpha$ 1.IL-4R $\alpha$ .Fc

C33 The IL-13R $\alpha$ 1 extracellular domain (including the signal peptide, therefore nts #34-1062; amino acid #1-343) was amplified by standard PCR techniques and ligated into an expression vector, pJFE14, to create an in-frame fusion upstream of the human IL-4Ra (nucleotides 236 through 868 (corresponding to the amino acids 21-231) from the Genbank sequence X52425) and human Fc. A ten amino acid linker with the amino acid sequence GAPSGGGGRP (SEQ ID NO: 6) was constructed in frame between the IL-4R $\alpha$  and the IL-13R $\alpha$ 1. The human IL-13R $\alpha$ 1 sequence was verified. The construct encoding this single chain trap was transfected into COS cells and protein expression was verified by Western Blot analysis of the cell media. The nucleotide and amino acid sequence of the IL-13R $\alpha$ 1.IL-4R $\alpha$ .Fc single chain trap is set forth in Figures 32A-32G (SEQ ID NOS: 31 and 32).

REMARKS

This amendment is being made merely to conform the specification to the formal drawings that are being submitted herewith and to insert sequence identifiers. The drawing changes and amendment are needed in order to comply with the rules regarding drawings containing multiple views. Applicants submit herewith as Exhibit B: Marked -Up Versions of pages 7, 8, 9, 10, 11, 12, 13, 41, 42, 49, 50, 51, 52, 53, 55, 56, 61, 62, and 64; and Exhibit C: Formal Drawings (59 sheets).


Att. Docket No.: REG 2009-A  
USSN 09/313,942  
Amendment Under 37 C.F.R. §1.312  
And Transmittal Of Formal Drawings

Applicants contend that no new matter is introduced by these Amendments and Drawing corrections and therefore respectfully request entry of the Amendments and Corrections to the Drawings.

Applicants submit herewith as Exhibit D: copy of the Transmittal of Sequence Listing which is being submitted concurrently.

No fee is deemed necessary in connection with this submission. However, if any fee is deemed necessary, authorization is hereby given to charge the fee to Deposit Account No. 18-0650.

Respectfully submitted,



Linda O. Palladino  
Reg. No. 45,636  
Patent Agent for Applicants  
Gail M. Kempler  
Reg. No. 32,143  
Joseph M. Sorrentino  
Reg. No. 32,598  
Laura J. Fischer  
Reg. No. P-50,420  
Attorneys for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400